Whether bridging therapy affects the outcomes of patients with lymphoma who receive CAR-T is unknown. Here, Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, explains the characteristics and outcomes of large B-cell lymphoma patients receiving bridging therapy while awaiting axicabtagene ciloleucel therapy from the US Lymphoma CAR T Consortium analysis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Speaker: Michael Jain,Event: ASH 2019,Format: Interview,Field: CAR-T & Cellular Therapy,Field: Immuno-Oncology,Medicines: CAR-T,Subject: Diffuse Large B-Cell Lymphoma,Subject: Lymphoma,Subject: Non-Hodgkin Lymphoma,Subject: B-Cell Lymphoma,real world data,Medicines: Axicabtagene ciloleucel,US Lymphoma CAR T Consortium,CD19,bridging therapy,
Whether bridging therapy affects the outcomes of patients with lymphoma who receive CAR-T is unknown. Here, Michael Jain, MD, PhD, Moffitt Cancer Center, Tampa, FL, explains the characteristics and outcomes of large B-cell lymphoma patients receiving bridging therapy while awaiting axicabtagene ciloleucel therapy from the US Lymphoma CAR T Consortium analysis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
0 Comments